ESH MDS 2024 | Key clinical trials in MDS taking place in the US

In this video, Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the ongoing and upcoming clinical trials in myelodysplastic syndromes (MDS) at the MD Anderson Cancer Center. Prof. Garcia-Manero highlights that, historically, the primary focus has been on studying high-risk disease; however, a significant increase has recently been observed in the number of trials investigating treatment approaches for lower-risk disease and precursor conditions, such as cytopenia of undetermined significance (CCUS). Despite a large number of studies being conducted, Prof. Garcia-Manero suggests there is a lack of studies in patients with TP53-mutated disease and those who experience treatment failure with frontline hypomethylating agents (HMAs). This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.